Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 353 entries
Sorted by: Best Match Show Resources per page
The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial.

The journal of family planning and reproductive health care

Singata-Madliki M, Hofmeyr GJ, Lawrie TA.
PMID: 27030698
J Fam Plann Reprod Health Care. 2016 Jul;42(3):171-6. doi: 10.1136/jfprhc-2015-101334. Epub 2016 Mar 30.

BACKGROUND: Depot medroxyprogesterone acetate (DMPA) is the most commonly used hormonal contraceptive method in South Africa. It is frequently administered in the immediate postnatal period, yet it is unclear whether it affects the risk of postnatal depression (PND).AIM: To...

Cite
Singata-Madliki M, Hofmeyr GJ, Lawrie TA. The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. J Fam Plann Reprod Health Care. 2016;42(3):171-6doi: 10.1136/jfprhc-2015-101334.
Singata-Madliki, M., Hofmeyr, G. J., & Lawrie, T. A. (2016). The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. The journal of family planning and reproductive health care, 42(3), 171-6. https://doi.org/10.1136/jfprhc-2015-101334
Singata-Madliki, Mandisa, et al. "The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial." The journal of family planning and reproductive health care vol. 42,3 (2016): 171-6. doi: https://doi.org/10.1136/jfprhc-2015-101334
Singata-Madliki M, Hofmeyr GJ, Lawrie TA. The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. J Fam Plann Reprod Health Care. 2016 Jul;42(3):171-6. doi: 10.1136/jfprhc-2015-101334. Epub 2016 Mar 30. PMID: 27030698.
Copy Download .nbib Format: NLM
Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report.

SpringerPlus

Tasaka N, Matsumoto K, Satoh T, Minaguchi T, Onuki M, Ochi H, Tanaka YO, Sakata A, Noguchi M, Yoshikawa H.
PMID: 24324925
Springerplus. 2013 Nov 20;2:618. doi: 10.1186/2193-1801-2-618. eCollection 2013.

Dienogest is a novel synthesized progestin used for treatment of endometriosis. This is the first case report describing a therapeutic effect of dienogest on a gynecologic malignancy. The patient was a 44-year-old woman with advanced adenosarcoma arising from the...

Cite
Tasaka N, Matsumoto K, Satoh T, et al. Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report. Springerplus. 2013;2:618doi: 10.1186/2193-1801-2-618.
Tasaka, N., Matsumoto, K., Satoh, T., Minaguchi, T., Onuki, M., Ochi, H., Tanaka, Y. O., Sakata, A., Noguchi, M., & Yoshikawa, H. (2013). Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report. SpringerPlus, 2618. https://doi.org/10.1186/2193-1801-2-618
Tasaka, Nobutaka, et al. "Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report." SpringerPlus vol. 2 (2013): 618. doi: https://doi.org/10.1186/2193-1801-2-618
Tasaka N, Matsumoto K, Satoh T, Minaguchi T, Onuki M, Ochi H, Tanaka YO, Sakata A, Noguchi M, Yoshikawa H. Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report. Springerplus. 2013 Nov 20;2:618. doi: 10.1186/2193-1801-2-618. eCollection 2013. PMID: 24324925; PMCID: PMC3855919.
Copy Download .nbib Format: NLM
Endocrine MPA enhances the effects of TAC chemotherapy on improvement of prognosis and increase in long-term survival rates for patients with endometrial cancer.

Oncology letters

Yuan X, Wang LU, Xue J, Li LI, Zhang J.
PMID: 26622772
Oncol Lett. 2015 Sep;10(3):1902-1906. doi: 10.3892/ol.2015.3395. Epub 2015 Jun 19.

The aim of the present study was to investigate the effect of taxol, adriamycin and carboplatin (TAC) chemotherapy combined with endocrine medroxyprogesterone acetate (MPA) therapy for the treatment of patients with endometrial cancer. A retrospective analysis of 124 patients...

Cite
Yuan X, Wang LU, Xue J, et al. Endocrine MPA enhances the effects of TAC chemotherapy on improvement of prognosis and increase in long-term survival rates for patients with endometrial cancer. Oncol Lett. 2015;10(3):1902-1906doi: 10.3892/ol.2015.3395.
Yuan, X., Wang, L. U., Xue, J., Li, L. I., & Zhang, J. (2015). Endocrine MPA enhances the effects of TAC chemotherapy on improvement of prognosis and increase in long-term survival rates for patients with endometrial cancer. Oncology letters, 10(3), 1902-1906. https://doi.org/10.3892/ol.2015.3395
Yuan, Xiuhong, et al. "Endocrine MPA enhances the effects of TAC chemotherapy on improvement of prognosis and increase in long-term survival rates for patients with endometrial cancer." Oncology letters vol. 10,3 (2015): 1902-1906. doi: https://doi.org/10.3892/ol.2015.3395
Yuan X, Wang LU, Xue J, Li LI, Zhang J. Endocrine MPA enhances the effects of TAC chemotherapy on improvement of prognosis and increase in long-term survival rates for patients with endometrial cancer. Oncol Lett. 2015 Sep;10(3):1902-1906. doi: 10.3892/ol.2015.3395. Epub 2015 Jun 19. PMID: 26622772; PMCID: PMC4533712.
Copy Download .nbib Format: NLM
Analytical Method Validation of High-Performance Liquid Chromatography and Stability-Indicating Study of Medroxyprogesterone Acetate Intravaginal Sponges.

Analytical chemistry insights

Batrawi N, Wahdan S, Abualhasan M.
PMID: 28469407
Anal Chem Insights. 2017 Feb 20;12:1177390117690152. doi: 10.1177/1177390117690152. eCollection 2017.

Medroxyprogesterone acetate is widely used in veterinary medicine as intravaginal dosage for the synchronization of breeding cycle in ewes and goats. The main goal of this study was to develop reverse-phase high-performance liquid chromatography method for the quantification of...

Cite
Batrawi N, Wahdan S, Abualhasan M. Analytical Method Validation of High-Performance Liquid Chromatography and Stability-Indicating Study of Medroxyprogesterone Acetate Intravaginal Sponges. Anal Chem Insights. 2017;12:1177390117690152doi: 10.1177/1177390117690152.
Batrawi, N., Wahdan, S., & Abualhasan, M. (2017). Analytical Method Validation of High-Performance Liquid Chromatography and Stability-Indicating Study of Medroxyprogesterone Acetate Intravaginal Sponges. Analytical chemistry insights, 121177390117690152. https://doi.org/10.1177/1177390117690152
Batrawi, Nidal, et al. "Analytical Method Validation of High-Performance Liquid Chromatography and Stability-Indicating Study of Medroxyprogesterone Acetate Intravaginal Sponges." Analytical chemistry insights vol. 12 (2017): 1177390117690152. doi: https://doi.org/10.1177/1177390117690152
Batrawi N, Wahdan S, Abualhasan M. Analytical Method Validation of High-Performance Liquid Chromatography and Stability-Indicating Study of Medroxyprogesterone Acetate Intravaginal Sponges. Anal Chem Insights. 2017 Feb 20;12:1177390117690152. doi: 10.1177/1177390117690152. eCollection 2017. PMID: 28469407; PMCID: PMC5345923.
Copy Download .nbib Format: NLM
Women's willingness to use emergency contraception: Experience at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde

Lukhaimane TA, Adam Y.
PMID: 26294863
S Afr Med J. 2015 Apr;105(4):266-7. doi: 10.7196/samj.9411.

Access to emergency contraception (EC) has little restriction in South Africa. EC is a contraceptive method that can be used by women up to 7 days after unprotected intercourse. It can be used in the following situations: when no...

Cite
Lukhaimane TA, Adam Y. Women's willingness to use emergency contraception: Experience at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa. S Afr Med J. 2015;105(4):266-7doi: 10.7196/samj.9411.
Lukhaimane, T. A., & Adam, Y. (2015). Women's willingness to use emergency contraception: Experience at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 105(4), 266-7. https://doi.org/10.7196/samj.9411
Lukhaimane, T A, and Adam, Y. "Women's willingness to use emergency contraception: Experience at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa." South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde vol. 105,4 (2015): 266-7. doi: https://doi.org/10.7196/samj.9411
Lukhaimane TA, Adam Y. Women's willingness to use emergency contraception: Experience at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa. S Afr Med J. 2015 Apr;105(4):266-7. doi: 10.7196/samj.9411. PMID: 26294863.
Copy Download .nbib Format: NLM
Reduction in the level of antibodies against heat shock proteins 60 during different hormonal protocols in postmenopausal women.

Przeglad menopauzalny = Menopause review

Rajtar-Ciosek A, Kacalska-Janssen O, Zmaczyński A, Wyroba J, Tomczyk R, Wiatr J, Gałuszka-Bednarczyk A, Bereza T, Milewicz T, Krzysiek J.
PMID: 26848292
Prz Menopauzalny. 2015 Dec;14(4):218-22. doi: 10.5114/pm.2015.56402. Epub 2015 Dec 16.

INTRODUCTION: In current literature, the immune-inflammatory theory of atherosclerosis is widely discussed. The role of how heat shock proteins 60 (HSP60) lead to the development of the atheromatous plaque is especially underlined. The aim of the study is to...

Cite
Rajtar-Ciosek A, Kacalska-Janssen O, Zmaczyński A, et al. Reduction in the level of antibodies against heat shock proteins 60 during different hormonal protocols in postmenopausal women. Prz Menopauzalny. 2015;14(4):218-22doi: 10.5114/pm.2015.56402.
Rajtar-Ciosek, A., Kacalska-Janssen, O., Zmaczyński, A., Wyroba, J., Tomczyk, R., Wiatr, J., Gałuszka-Bednarczyk, A., Bereza, T., Milewicz, T., & Krzysiek, J. (2015). Reduction in the level of antibodies against heat shock proteins 60 during different hormonal protocols in postmenopausal women. Przeglad menopauzalny = Menopause review, 14(4), 218-22. https://doi.org/10.5114/pm.2015.56402
Rajtar-Ciosek, Agnieszka, et al. "Reduction in the level of antibodies against heat shock proteins 60 during different hormonal protocols in postmenopausal women." Przeglad menopauzalny = Menopause review vol. 14,4 (2015): 218-22. doi: https://doi.org/10.5114/pm.2015.56402
Rajtar-Ciosek A, Kacalska-Janssen O, Zmaczyński A, Wyroba J, Tomczyk R, Wiatr J, Gałuszka-Bednarczyk A, Bereza T, Milewicz T, Krzysiek J. Reduction in the level of antibodies against heat shock proteins 60 during different hormonal protocols in postmenopausal women. Prz Menopauzalny. 2015 Dec;14(4):218-22. doi: 10.5114/pm.2015.56402. Epub 2015 Dec 16. PMID: 26848292; PMCID: PMC4733899.
Copy Download .nbib Format: NLM
The important application of thioridazine in the endometrial cancer.

American journal of translational research

Meng Q, Sun X, Wang J, Wang Y, Wang L.
PMID: 27398159
Am J Transl Res. 2016 Jun 15;8(6):2767-75. eCollection 2016.

BACKGROUND: Endometrial cancer (ECa) is one of the serious healthy burden for female worldwide. The treatments of ECa focus on the application of endocrine therapy and aberrant signaling proteins expression recently years. Medroxyprogesterone acrtate (MPA) plays crucial role in...

Cite
Meng Q, Sun X, Wang J, et al. The important application of thioridazine in the endometrial cancer. Am J Transl Res. 2016;8(6):2767-75
Meng, Q., Sun, X., Wang, J., Wang, Y., & Wang, L. (2016). The important application of thioridazine in the endometrial cancer. American journal of translational research, 8(6), 2767-75.
Meng, Qiong, et al. "The important application of thioridazine in the endometrial cancer." American journal of translational research vol. 8,6 (2016): 2767-75.
Meng Q, Sun X, Wang J, Wang Y, Wang L. The important application of thioridazine in the endometrial cancer. Am J Transl Res. 2016 Jun 15;8(6):2767-75. eCollection 2016. PMID: 27398159; PMCID: PMC4931170.
Copy Download .nbib Format: NLM
New insight on a possible mechanism of progestogens in terms of breast cancer risk.

Hormone molecular biology and clinical investigation

Neubauer H, Chen R, Schneck H, Knorrp T, Templin MF, Fehm T, Cahill MA, Seeger H, Yu Q, Mueck AO.
PMID: 25961254
Horm Mol Biol Clin Investig. 2011 Apr 01;6(1):185-92. doi: 10.1515/HMBCI.2010.082.

OBJECTIVES: Progestogens influence mammary gland development and probably breast cancer tumorigenesis by regulating a broad spectrum of physiological processes. We investigated receptor membrane-initiated actions of progestogens in MCF-7 breast cancer cells overexpressing progesterone receptor membrane component 1 (PGRMC1).DESIGN: MCF-7...

Cite
Neubauer H, Chen R, Schneck H, et al. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Investig. 2011;6(1):185-92doi: 10.1515/HMBCI.2010.082.
Neubauer, H., Chen, R., Schneck, H., Knorrp, T., Templin, M. F., Fehm, T., Cahill, M. A., Seeger, H., Yu, Q., & Mueck, A. O. (2011). New insight on a possible mechanism of progestogens in terms of breast cancer risk. Hormone molecular biology and clinical investigation, 6(1), 185-92. https://doi.org/10.1515/HMBCI.2010.082
Neubauer, Hans, et al. "New insight on a possible mechanism of progestogens in terms of breast cancer risk." Hormone molecular biology and clinical investigation vol. 6,1 (2011): 185-92. doi: https://doi.org/10.1515/HMBCI.2010.082
Neubauer H, Chen R, Schneck H, Knorrp T, Templin MF, Fehm T, Cahill MA, Seeger H, Yu Q, Mueck AO. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Investig. 2011 Apr 01;6(1):185-92. doi: 10.1515/HMBCI.2010.082. PMID: 25961254.
Copy Download .nbib Format: NLM
Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells.

Hormone molecular biology and clinical investigation

Seeger H, Ruan X, Neubauer H, Mueck AO.
PMID: 25961257
Horm Mol Biol Clin Investig. 2011 May 01;6(2):211-4. doi: 10.1515/HMBCI.2011.008.

BACKGROUND: Proliferation of human breast epithelial cells is regulated by sex hormones. Epidemiological studies indicate that progestogen addition to estrogen therapy can increase breast cancer risk. However, it remains unclear if all progestogens react in a similar manner. Here,...

Cite
Seeger H, Ruan X, Neubauer H, et al. Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. Horm Mol Biol Clin Investig. 2011;6(2):211-4doi: 10.1515/HMBCI.2011.008.
Seeger, H., Ruan, X., Neubauer, H., & Mueck, A. O. (2011). Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. Hormone molecular biology and clinical investigation, 6(2), 211-4. https://doi.org/10.1515/HMBCI.2011.008
Seeger, Harald, et al. "Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells." Hormone molecular biology and clinical investigation vol. 6,2 (2011): 211-4. doi: https://doi.org/10.1515/HMBCI.2011.008
Seeger H, Ruan X, Neubauer H, Mueck AO. Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. Horm Mol Biol Clin Investig. 2011 May 01;6(2):211-4. doi: 10.1515/HMBCI.2011.008. PMID: 25961257.
Copy Download .nbib Format: NLM
Cancer cachexia, mechanism and treatment.

World journal of gastrointestinal oncology

Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K.
PMID: 25897346
World J Gastrointest Oncol. 2015 Apr 15;7(4):17-29. doi: 10.4251/wjgo.v7.i4.17.

It is estimated that half of all patients with cancer eventually develop a syndrome of cachexia, with anorexia and a progressive loss of adipose tissue and skeletal muscle mass. Cancer cachexia is characterized by systemic inflammation, negative protein and...

Cite
Aoyagi T, Terracina KP, Raza A, et al. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015;7(4):17-29doi: 10.4251/wjgo.v7.i4.17.
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015). Cancer cachexia, mechanism and treatment. World journal of gastrointestinal oncology, 7(4), 17-29. https://doi.org/10.4251/wjgo.v7.i4.17
Aoyagi, Tomoyoshi, et al. "Cancer cachexia, mechanism and treatment." World journal of gastrointestinal oncology vol. 7,4 (2015): 17-29. doi: https://doi.org/10.4251/wjgo.v7.i4.17
Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015 Apr 15;7(4):17-29. doi: 10.4251/wjgo.v7.i4.17. PMID: 25897346; PMCID: PMC4398892.
Copy Download .nbib Format: NLM
CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer.

Breast cancer (Tokyo, Japan)

Wada T, Nishiyama K, Nakatani Y, Houjou T, Inui H, Yamauchi E, Hara S, Yasutomi M.
PMID: 11091534
Breast Cancer. 1995 Apr 30;2(1):65-70. doi: 10.1007/BF02966898.

A controlled randomized trial was conducted to compare the effectiveness of a CAF therapy including cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5FU) with that of CAF plus medroxyprogesterone acetate (MPA) therapy including CPA, ADR and 5FU plus MPA for...

Cite
Wada T, Nishiyama K, Nakatani Y, et al. CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer. Breast Cancer. 1995;2(1):65-70doi: 10.1007/BF02966898.
Wada, T., Nishiyama, K., Nakatani, Y., Houjou, T., Inui, H., Yamauchi, E., Hara, S., & Yasutomi, M. (1995). CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer. Breast cancer (Tokyo, Japan), 2(1), 65-70. https://doi.org/10.1007/BF02966898
Wada, et al. "CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer." Breast cancer (Tokyo, Japan) vol. 2,1 (1995): 65-70. doi: https://doi.org/10.1007/BF02966898
Wada T, Nishiyama K, Nakatani Y, Houjou T, Inui H, Yamauchi E, Hara S, Yasutomi M. CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer. Breast Cancer. 1995 Apr 30;2(1):65-70. doi: 10.1007/BF02966898. PMID: 11091534.
Copy Download .nbib Format: NLM
A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil.

Breast cancer (Tokyo, Japan)

Kuroi K, Osaki A, Kawami H, Murakami S, Toge T.
PMID: 11091585
Breast Cancer. 1997 Jul 31;4(2):115-119. doi: 10.1007/BF02967064.

Thirty-two patients with advanced breast cancer refractory to combination chemotherapy with cyclophosphamide (CPA), doxorubicin (ADR) and 5-fluorouracil (5-EU) (CAF) were treated with the combination of mitomycin C, etoposide, doxifluridine and medroxyprogesterone acetate as second line therapy. Observed responses included...

Cite
Kuroi K, Osaki A, Kawami H, et al. A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil. Breast Cancer. 1997;4(2):115-119doi: 10.1007/BF02967064.
Kuroi, K., Osaki, A., Kawami, H., Murakami, S., & Toge, T. (1997). A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil. Breast cancer (Tokyo, Japan), 4(2), 115-119. https://doi.org/10.1007/BF02967064
Kuroi, et al. "A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil." Breast cancer (Tokyo, Japan) vol. 4,2 (1997): 115-119. doi: https://doi.org/10.1007/BF02967064
Kuroi K, Osaki A, Kawami H, Murakami S, Toge T. A Combination Therapy with Mitomycin C, Etoposide, Doxifluridine and Medroxyprogesterone Acetate as Second Line Therapy for Advanced Breast Cancer Refractory to Combination Chemotherapy of Cyclo-phoshamide, Doxorubicin and 5-Fluorouracil. Breast Cancer. 1997 Jul 31;4(2):115-119. doi: 10.1007/BF02967064. PMID: 11091585.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 353 entries